RxDoctor Payments Data

Christopher McNeill, MD

Family Medicine · Valrico, FLNPI 1952756827

Payments from drug & device makers

$7,178in general payments, 2019–2025

Across 390 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$944
  • AbbVie$903
  • GSK$739
  • Pfizer$469
  • AstraZeneca$450
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$434
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$7,164100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,178 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$116,764
Medicare patients
158
Services billed
3,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide163$177,624
FarxigaDapagliflozin Propanediol136$125,842
EliquisApixaban56$53,976
RybelsusSemaglutide32$42,006
JardianceEmpagliflozin35$39,258
MounjaroTirzepatide31$33,782
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$30,213
JanuviaSitagliptin Phosphate17$15,296
TrulicityDulaglutide13$14,586
KerendiaFinerenone19$12,309
Tresiba Flextouch U-100Insulin Degludec16$5,224
Varenicline Tartrate13$5,024
Rosuvastatin Calcium365$3,457
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,223
Atorvastatin Calcium382$3,193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Levemir$944$221,904207 claims
AstraZenecaFarxiga, Breztri Aerosphere$450$156,056167 claims
PfizerEliquis$469$53,97656 claims
Lilly USA, LLCMounjaro, Trulicity$394$48,36844 claims
Boehringer IngelheimJardiance$22$39,25835 claims
MerckJanuvia$138$15,29617 claims
BayerKerendia$307$12,30919 claims
AbbVieSynthroid$903$1,42519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Valrico

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →